
Opinion|Videos|June 28, 2024
Review of MOA and Effectiveness of Current Treatments
Hematologic oncologists review therapeutic options for patients with chronic GVHD and provide clinical insights on their treatment approaches.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Please discuss the effectiveness of the most used systemic treatment options.
- How do you sequence treatments for chronic GVHD?
- What are the most pressing challenges faced by healthcare providers in effectively managing cGVHD, particularly in patients who have progressed through multiple treatment lines?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















